HM Payson & Co. Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

HM Payson & Co. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 29.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 800 shares of the medical device company’s stock after selling 330 shares during the quarter. HM Payson & Co.’s holdings in DexCom were worth $62,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Blue Whale Capital LLP boosted its position in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares in the last quarter. Brooktree Capital Management purchased a new stake in shares of DexCom in the 3rd quarter worth about $683,000. Motley Fool Asset Management LLC grew its stake in DexCom by 168.7% in the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock valued at $17,993,000 after acquiring an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC purchased a new position in DexCom during the 4th quarter valued at about $3,334,000. Finally, Congress Asset Management Co. raised its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after acquiring an additional 1,332,522 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

DXCM opened at $77.84 on Monday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a market cap of $30.42 billion, a P/E ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $84.83 and a two-hundred day moving average of $77.01.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DXCM. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Citigroup boosted their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.